Search results
Results from the WOW.Com Content Network
Although no clinical development took place, Axovant held its IPO in June 2015 and raised $315 million, [4] the largest biotech IPO ever, [9] based on new phase IIB trials that were more promising. [10] The lock-up period against reselling stock was reduced to an unusually short 90 days for hedge funds that showed interest in the IPO. [11]
For premium support please call: 800-290-4726 more ways to reach us
Already a multibillion-dollar market, one researcher believes the lupus nephritis treatment market will grow at 11% a year through 2033 to $5.7 billion. Artiva hopes to use the treatment for ...
Need help? Call us! 800-290-4726 Login / Join. Mail
The following table lists the largest biotechnology and pharmaceutical companies ranked by market capitalization in billion US dollars. The change column indicates the company's relative position in this list compared to their relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
The IPO market finally loosened up in late 2023 after one of the worst periods for debuts in more than a decade. Rapidly rising interest rates – courtesy of an aggressive Federal Reserve ...
The two companies had agreed to a $54 billion deal that would allow AbbVie to move its headquarters overseas to Europe, reducing their corporate tax rate. However, the U.S. Treasury passed laws, tightening down on tax inversion deals just before the merger was completed, making the agreement much less profitable for AbbVie. [citation needed] 15 ...